Literature DB >> 1716510

Prostate-specific antigen levels from completely sectioned, clinically benign, whole prostates.

P N Brawn1, V O Speights, D Kuhl, M Riggs, A M Spiekerman, R G McCord, K S Coffield, D T Stewart, M L Lind.   

Abstract

Clinically benign whole, untrimmed prostates and pelvic lymph nodes were obtained from 105 patients at autopsy. All 105 patients had premortem serum from which prostate-specific antigen (PSA) levels were obtained. Sixty-eight did not have carcinoma of the prostate (CAP), 28 had CAP less than 1 ml and 9 had CAP larger than 1 ml. Eleven untrimmed prostates weighed 80 g or more and eight had elevated PSA levels (more than 4.0 ng/ml): five of eight without CAP, two of two with CAP less than 1 ml, and one of one with CAP larger than 1 ml. Ninety-four whole untrimmed prostates weighed less than 80 g and 20 had elevated PSA levels: ten of 60 without CAP, two of 26 with CAP less than 1 ml, and eight of eight with CAP larger than 1 ml. This study suggests that PSA levels from patients with untrimmed prostates weighing 80 g or more (equivalent to a 60-g trimmed prostate) are usually elevated regardless whether CAP is present. However, CAP less than 1 ml, in untrimmed prostates less than 80 g, usually does not elevate PSA levels whereas CAP larger than 1 ml usually does (P less than 0.0001). The likelihood that elevated PSA levels, from patients with untrimmed prostates less than 80 g, are due to CAP larger than 1 ml increases as the PSA level increases.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1716510     DOI: 10.1002/1097-0142(19911001)68:7<1592::aid-cncr2820680721>3.0.co;2-m

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

1.  Prostate cancers in men with low PSA levels--must we find them?

Authors:  H Ballentine Carter
Journal:  N Engl J Med       Date:  2004-05-27       Impact factor: 91.245

2.  The correlation of extent and grade of inflammation with serum PSA levels in patients with IV prostatitis.

Authors:  Li Gui-Zhong; Man Libo; Huang Guanglin; Wang Jianwei
Journal:  Int Urol Nephrol       Date:  2010-09-05       Impact factor: 2.370

3.  Defining aggressive prostate cancer using a 12-gene model.

Authors:  Tarek A Bismar; Francesca Demichelis; Alberto Riva; Robert Kim; Sooryanarayana Varambally; Le He; Jeff Kutok; Jonathan C Aster; Jeffery Tang; Rainer Kuefer; Matthias D Hofer; Phillip G Febbo; Arul M Chinnaiyan; Mark A Rubin
Journal:  Neoplasia       Date:  2006-01       Impact factor: 5.715

4.  Prostate biopsy in subjects with abnormal transrectal ultrasonography but normal digital examination findings and prostate-specific antigen levels.

Authors:  Hong Bang Shim; Sang Eun Lee; Hyoung Keun Park; Ja Hyeon Ku
Journal:  Int Urol Nephrol       Date:  2007-07-03       Impact factor: 2.370

5.  The effect of antibiotherapy on prostate-specific antigen levels and prostate biopsy results in patients with levels 2.5 to 10 ng/mL.

Authors:  Gokhan Toktas; Murat Demiray; Erkan Erkan; Ramazan Kocaaslan; Ugur Yucetas; Suleyman Erdinc Unluer
Journal:  J Endourol       Date:  2013-08       Impact factor: 2.942

Review 6.  Prostatitis and serum prostate-specific antigen.

Authors:  Puneet Sindhwani; Christopher M Wilson
Journal:  Curr Urol Rep       Date:  2005-07       Impact factor: 2.862

Review 7.  Prostatitis versus pelvic pain syndrome: immunologic studies.

Authors:  Caroline Maake; Hubert John
Journal:  Curr Urol Rep       Date:  2003-08       Impact factor: 2.862

Review 8.  Current Knowledge of the Potential Links between Inflammation and Prostate Cancer.

Authors:  Tommaso Cai; Raffaella Santi; Irene Tamanini; Ilaria Camilla Galli; Gianpaolo Perletti; Truls E Bjerklund Johansen; Gabriella Nesi
Journal:  Int J Mol Sci       Date:  2019-08-06       Impact factor: 5.923

9.  Long-term survival of stage A prostate carcinoma, atypical hyperplasia/adenosis and BPH.

Authors:  P N Brawn; E H Johnson; V O Speights; M Riggs; M Lind; N Bell
Journal:  Br J Cancer       Date:  1994-06       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.